#1 Clinical Trials Search in Europe

Imipenem Anhydrate

Imipenem Anhydrate, a powerful antibiotic, is currently being studied in clinical trials for its effectiveness in treating serious bacterial infections. These trials aim to evaluate how well the drug works, particularly when combined with other medications, in fighting complicated urinary tract infections, intra-abdominal infections, and other severe bacterial illnesses. The research focuses on comparing Imipenem Anhydrate to other treatments and assessing its safety and efficacy in different patient populations.

Table of Contents

What is Imipenem Anhydrate?

Imipenem Anhydrate is a powerful antibiotic medication that belongs to the carbapenem class of antibiotics. It is often combined with another drug called Cilastatin, which helps prevent the rapid breakdown of Imipenem in the body, allowing it to work more effectively[1]. The combination of these two drugs is known as Imipenem-Cilastatin.

Imipenem Anhydrate is also known by its synonym, Anhydrous Imipenem[1]. This medication is typically used to treat serious bacterial infections that are resistant to other antibiotics.

Medical Uses

Imipenem-Cilastatin is used to treat a variety of serious bacterial infections, including:

  • Complicated Urinary Tract Infections (cUTI): These are urinary tract infections that are more difficult to treat, often due to structural abnormalities in the urinary tract or the presence of resistant bacteria[2].
  • Acute Pyelonephritis (AP): This is a serious kidney infection that can cause fever, back pain, and other symptoms[2].
  • Hospital-Acquired Pneumonia (HAP): This is a lung infection that develops during a hospital stay[1].
  • Ventilator-Associated Pneumonia (VAP): This is a type of pneumonia that occurs in people who are on mechanical ventilation[1].
  • Intra-abdominal Infections: These are infections that occur within the abdomen[1].
  • Bloodstream Infections: Also known as bacteremia, these are serious infections where bacteria enter the bloodstream[1].

How It Works

Imipenem works by interfering with the cell wall synthesis of bacteria. It binds to certain proteins in the bacterial cell wall, preventing the bacteria from forming a proper cell wall. This ultimately leads to the death of the bacteria[2].

Cilastatin, which is combined with Imipenem, doesn’t have any antibacterial activity itself. Instead, it prevents an enzyme in the kidneys from breaking down Imipenem too quickly. This allows Imipenem to reach higher concentrations in the body and work more effectively against infections[2].

Administration

Imipenem-Cilastatin is typically administered intravenously (through a vein) in a hospital setting. The usual dose is 500 mg, given every 6 hours[2]. However, the exact dosage and duration of treatment can vary depending on the type and severity of the infection, as well as other factors such as the patient’s kidney function.

Effectiveness

Imipenem-Cilastatin is considered a broad-spectrum antibiotic, meaning it’s effective against a wide range of bacteria. It’s particularly useful for treating infections caused by bacteria that are resistant to other antibiotics[2].

In clinical trials, Imipenem-Cilastatin has shown effectiveness in treating various types of infections. For example, in a study comparing it to another antibiotic for treating complicated urinary tract infections and acute pyelonephritis, Imipenem-Cilastatin demonstrated comparable efficacy[2].

Safety and Side Effects

Like all medications, Imipenem-Cilastatin can cause side effects. Common side effects may include:

  • Nausea and vomiting
  • Diarrhea
  • Skin rash
  • Fever
  • Local reactions at the injection site

More serious side effects, although rare, can include allergic reactions, seizures, and changes in liver function. It’s important to report any unusual symptoms to your healthcare provider immediately[2].

Special Considerations

There are several important considerations when using Imipenem-Cilastatin:

  • Allergies: Patients with a history of allergic reactions to other beta-lactam antibiotics (such as penicillins or cephalosporins) may be at higher risk of an allergic reaction to Imipenem[2].
  • Kidney function: The dosage may need to be adjusted in patients with reduced kidney function[2].
  • Seizure risk: Imipenem may increase the risk of seizures in some patients, particularly those with a history of seizures or brain lesions[2].
  • Pregnancy and breastfeeding: The safety of Imipenem-Cilastatin during pregnancy and breastfeeding is not fully established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant[2].

In conclusion, Imipenem Anhydrate, typically used in combination with Cilastatin, is a powerful antibiotic used to treat serious bacterial infections. While it can be highly effective, it’s important to use it under close medical supervision due to the potential for side effects and the need to use antibiotics responsibly to prevent the development of antibiotic resistance.

Aspect Details
Drug Name Imipenem Anhydrate (often combined with Cilastatin)
Drug Class Carbapenem antibiotic
Administration Intravenous (IV)
Target Conditions Complicated urinary tract infections, acute pyelonephritis, intra-abdominal infections, hospital-acquired pneumonia, ventilator-associated pneumonia, bloodstream infections
Trial Phases Phase 2 and Phase 3
Key Objectives Assess efficacy, safety, and pharmacokinetics compared to other treatments
Patient Population Adults (typically 18 years and older)
Dosage Varies by trial, typically 500 mg IV every 6 hours
Treatment Duration Up to 14 days, depending on the trial and condition
Primary Endpoints Overall response (clinical cure and microbiological eradication), safety assessments

FAQ

  • What is Imipenem Anhydrate? Imipenem Anhydrate is a type of antibiotic used to treat serious bacterial infections. It belongs to a class of drugs called carbapenems, which are known for their broad-spectrum activity against many types of bacteria.
  • What types of infections are being studied in these clinical trials? The clinical trials are studying Imipenem Anhydrate's effectiveness against various serious infections, including complicated urinary tract infections (cUTI), acute pyelonephritis (AP), intra-abdominal infections, hospital-acquired pneumonia, and bloodstream infections.
  • How is Imipenem Anhydrate administered in these trials? In the trials, Imipenem Anhydrate is typically administered intravenously (through a vein) in combination with another drug called Cilastatin. The dosage and frequency may vary depending on the specific trial and patient condition.
  • Are there any side effects associated with Imipenem Anhydrate? Like all medications, Imipenem Anhydrate can have side effects. The clinical trials are designed to monitor and assess these effects. Common side effects of carbapenem antibiotics can include nausea, diarrhea, and headache. More serious side effects are rare but possible.
  • Who can participate in these clinical trials? Eligibility for these trials varies, but generally includes adult patients with specific types of bacterial infections. Each trial has its own set of inclusion and exclusion criteria, which may consider factors like age, type of infection, severity of illness, and overall health status.

Ongoing Clinical Trials on Imipenem Anhydrate

  • Study of Aztreonam-Avibactam and Metronidazole for Children with Serious Gram-Negative Bacterial Infections

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Greece Hungary Spain

  • Title: Comparison of oral tebipenem pivoxil versus intravenous imipenem-cilastatin in adults with complicated urinary tract infection or acute pyelonephritis

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Croatia Estonia Greece Hungary Latvia +3

Glossary

  • Imipenem Anhydrate: A broad-spectrum antibiotic belonging to the carbapenem class, used to treat serious bacterial infections.
  • Cilastatin: A drug often combined with Imipenem to prevent its rapid breakdown in the body, allowing it to be more effective.
  • Complicated Urinary Tract Infection (cUTI): A urinary tract infection that has additional factors making it more difficult to treat, such as structural abnormalities or catheterization.
  • Acute Pyelonephritis (AP): A sudden and severe kidney infection, often resulting from a lower urinary tract infection spreading to the kidneys.
  • Intra-abdominal Infection: An infection that occurs within the abdomen, which can involve various organs and tissues in that area.
  • Hospital-Acquired Pneumonia: A lung infection that develops during a hospital stay, typically 48 hours or more after admission.
  • Ventilator-Associated Pneumonia: A type of pneumonia that occurs in people who are on mechanical ventilation breathing machines in hospitals.
  • Bloodstream Infection: An infection where bacteria enter the blood, potentially leading to a serious condition called sepsis.
  • Intravenous (IV) Administration: A method of giving medications directly into a vein using a needle or tube.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Clinical Trial: A research study that tests how well new medical approaches work in people, often used to evaluate new treatments for diseases.

References

  1. http://clinicaltrials.eu/trial/study-of-aztreonam-avibactam-and-metronidazole-for-children-with-serious-gram-negative-bacterial-infections/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-oral-tebipenem-pivoxil-hydrobromide-vs-iv-imipenem-cilastatin-for-adults-with-complicated-urinary-tract-infections/